These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L; Norton JC; Chi-Burris K; Demos G CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976 [TBL] [Abstract][Full Text] [Related]
8. Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial. Weintraub D; Espay AJ; Sharma VD; Tariot PN; Abler V; Pathak S; Stankovic S Parkinsonism Relat Disord; 2024 Feb; 119():105951. PubMed ID: 38113700 [TBL] [Abstract][Full Text] [Related]
9. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis. Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817 [TBL] [Abstract][Full Text] [Related]
10. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis. Panchal SC; Ondo WG Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325 [TBL] [Abstract][Full Text] [Related]
11. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. Espay AJ; Guskey MT; Norton JC; Coate B; Vizcarra JA; Ballard C; Factor SA; Friedman JH; Lang AE; Larsen NJ; Andersson C; Fredericks D; Weintraub D Mov Disord; 2018 Nov; 33(11):1769-1776. PubMed ID: 30387904 [TBL] [Abstract][Full Text] [Related]
12. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563 [TBL] [Abstract][Full Text] [Related]
13. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis. Kianirad Y; Simuni T Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967 [TBL] [Abstract][Full Text] [Related]
16. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin. Majlath Z; Obal I; Vecsei L CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624 [TBL] [Abstract][Full Text] [Related]
17. Dementia-related psychosis and the potential role for pimavanserin. Cummings JL; Devanand DP; Stahl SM CNS Spectr; 2022 Feb; 27(1):7-15. PubMed ID: 32811586 [TBL] [Abstract][Full Text] [Related]
18. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis. Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643 [TBL] [Abstract][Full Text] [Related]
19. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. Sahli ZT; Tarazi FI Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Nasrallah HA; Fedora R; Morton R Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]